ADMS · Adamas Pharmaceuticals Inc.
Acquired Company
Supernus acquired Adamas Pharmaceuticals on 11/24/2021 for $8.10 per share in cash plus two non-transferable CVRs, representing up to $9.10 per share in total consideration.
Adamas Pharmaceuticals Inc. delivers innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. The company is a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases.
1900 Powell St Ste 1000, California, 94608-1839, US
Pharmaceutical Preparation Manufacturing
Manufacturing
Market Cap
N/A
52 Wk Range
N/A - N/A
Previous Close
$8.22
Open
$8.22
Volume
N/A
Day Range
$8.22 - $8.22
Enterprise Value
N/A
Cash
N/A
Avg Qtr Burn
N/A
Insider Ownership
N/A
Institutional Own.
N/A
Qtr Updated
Dec 31st 2024